CP-642959(CP-642959) - 药物靶点：50S subunit_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

50S subunit

作用方式

抑制剂

作用机制

50S subunit抑制剂(50S核糖体亚基抑制剂)

治疗领域

感染

在研适应症-

非在研适应症

细菌感染

原研机构

Pfizer Inc.

在研机构-

非在研机构

Pfizer Inc.

权益机构-

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 CP-642959 相关的临床结果

登录后查看更多信息

100 项与 CP-642959 相关的转化医学

登录后查看更多信息

100 项与 CP-642959 相关的专利（医药）

登录后查看更多信息

1

项与 CP-642959 相关的文献（医药）

2002-11-01·Nihon rinsho. Japanese journal of clinical medicine

[Recent trend for the development of new antibacterial agents].

Review

作者: Nishino, Takeshi

Multidrug resistant organisms such as MRSA, PRSP, BLNAR, ESBL-producing K. pneumoniae and VRE have in recent years emerged as significant pathogens in hospitals. In this paper, I describe the recent trend for the development of new antibacterial agents that are active against these multidrug resistant organisms. A number of new cephem and carbapenem antibiotics were identified to have attractive potency against MRSA, PRSP and P. aeruginosa. These beta-lactam antibiotics had high affinity for PBP 2a of MRSA. AM-112 is a novel beta-lactamase inhibitor that has potent activity against class A, B, C and D beta-lactamases. Telithromycin, ABT-773, CP-642959 and A-217213, ketolide antimicrobials, possess several distinguishing features that are important for these microbiological profile. New extended-spectrum fluoroquinolones(BMS-284756, DQ-113, DK-570 k) with improved activity against Gram-positive pathogens have recently licensed for treatment of RTIs. Drug efflux pumps inhibitors are now under basic research.

100 项与 CP-642959 相关的药物交易

登录后查看更多信息